[Oral and intravenous @entity8633 in the treatment of recurrent sustained XXXX . Electropharmacological study].

@entity1 @entity1165 @entity8442 @entity591 @entity1817 @entity8633
The antiarrhythmic properties of @entity8633 on @entity1165 ( @entity1165 ) termination and prevention were studied in 16 @entity1 using programmed electrical stimulation techniques. All @entity1 were admitted for documented sustained @entity1165 resistant to 3.5 +/- 2.4 antiarrhythmic agents. Intravenous @entity8633 (2 mg/kg) successfully terminated 4 out of 8 and prevented 3 out of 8 @entity1 with hemodynamically well tolerated sustained @entity1165 . Oral @entity8633 (800 mg day 500-600 mg the following days) prevented successfully pacing-induced @entity1165 in 7 @entity1 (43.7 p. cent) and a partial result was obtained in additional 3 (18.7 p. cent). In 6 @entity1 @entity8633 failed to prevent pacing-induced @entity1165 including 2 @entity1 with a shorter cycle length on @entity8633 (classified as aggravation). @entity591 cycle length lengthened in the remaining 4 a mean of 11 +/- 12 p. cent. One of the 7 @entity1 with a good result presented on @entity8633 evidence of @entity1817 . The remaining 6 underwent long-term therapy (600 mg/24 h). During a mean follow up of 19 +/- 4 months, 4 @entity1 are well controlled, 1 presented a side-effect ( @entity8442 ) and 1 a recurrence. This study emphasizes the antiarrhythmic properties of @entity8633 at the ventricular level and provides evidence of its usefulness in @entity1 with recurrent sustained @entity1165 .
